Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of  FLT3.
Joaquín
J
Martínez-López
Nerea
N
Castro
Daniel
D
Rueda
Alicia
A
Canal
Carlos
C
Grande
Rosa
R
Ayala
D000368:Aged; D000595:Amino Acid Sequence; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008969:Molecular Sequence Data; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D017354:Point Mutation; D011725:Pyridines / Q000627:therapeutic use*; D016415:Sequence Alignment; D000077157:Sorafenib; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3